AstraZeneca Plc on Monday reported Phase 3 EMERALD-3 trial results showing that its immunotherapy-based STRIDE regimen, when ...

AstraZeneca added to its Imfinzi armamentarium on Monday after the immuno-oncology drug led to improved survival in liver ...

CHICAGO — For the first time, doctors say they have found a pill that improves survival in liver cancer, a notoriously hard-to-treat disease diagnosed in more than half a million people globally each ...

Adding an immunotherapy-based regimen to standard treatment may improve outcomes for some patients with liver cancer who are ...

The risk of dying from the most common form of primary liver cancer is about 30 percent higher for patients with low household income compared to those with middle or high household income, according ...

AstraZeneca is polishing the case for its Imfinzi (durvalumab) and Imjudo (tremelimumab) combo in liver cancer with a new ...

Researchers at the University of Massachusetts Amherst have designed non-toxic Salmonella bacteria to deliver viruses that ...

Cancer of the liver, seen in a radial cross-section abdominal scan. (Photo by: BSIP/Universal Images Group via Getty Images) The number of new liver cancer cases will nearly double in the next 25 ...